KalVista Pharmaceuticals (KALV) to Release Earnings on Tuesday

KalVista Pharmaceuticals (NASDAQ:KALV) is expected to issue its results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.96) per share and revenue of $6.0330 million for the quarter.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.97 million. On average, analysts expect KalVista Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

KalVista Pharmaceuticals Stock Down 0.4%

NASDAQ KALV traded down $0.04 during trading hours on Tuesday, hitting $10.76. The company’s stock had a trading volume of 739,348 shares, compared to its average volume of 887,402. The stock has a fifty day moving average of $12.59 and a 200 day moving average of $12.87. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $17.28. The firm has a market capitalization of $543.63 million, a P/E ratio of -2.73 and a beta of -0.15.

Insider Activity

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,336 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $13.42, for a total value of $31,349.12. Following the transaction, the insider directly owned 122,505 shares of the company’s stock, valued at $1,644,017.10. This represents a 1.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $15.84, for a total transaction of $115,536.96. Following the completion of the sale, the chief executive officer owned 395,189 shares of the company’s stock, valued at $6,259,793.76. This trade represents a 1.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 26,856 shares of company stock valued at $374,910 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter valued at about $248,000. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 816.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after buying an additional 7,180 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in KalVista Pharmaceuticals by 78.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 46,901 shares of the specialty pharmaceutical company’s stock valued at $530,000 after buying an additional 20,632 shares during the last quarter. BNP Paribas Financial Markets boosted its position in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Finally, Brevan Howard Capital Management LP bought a new stake in KalVista Pharmaceuticals during the 2nd quarter worth approximately $151,000.

Analyst Upgrades and Downgrades

KALV has been the topic of several recent analyst reports. JMP Securities lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Leerink Partners lifted their target price on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, July 7th. HC Wainwright boosted their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $26.43.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).